Nano-X Imaging Receives FDA 510(k) Clearance for Nanox.ARC
Ticker: NNOX · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1795251
Sentiment: bullish
Topics: fda-clearance, medical-device, nanox
TL;DR
FDA clears Nano-X Imaging's Nanox.ARC X-ray system for general use!
AI Summary
On December 5, 2024, Nano-X Imaging Ltd. announced it received 510(k) clearance from the FDA for its Nanox.ARC stationary X-ray system. This system is designed for general use in producing tomographic images of the human musculoskeletal system, pulmonary, intra-abdominal, and paranasal sinus indications in adult patients.
Why It Matters
This FDA clearance is a significant milestone for Nano-X Imaging, potentially enabling wider adoption and commercialization of their novel X-ray technology in the U.S. market.
Risk Assessment
Risk Level: medium — While FDA clearance is positive, the company's commercial success and market penetration remain to be seen, and regulatory hurdles can be complex.
Key Players & Entities
- Nano-X Imaging Ltd. (company) — The company that received FDA clearance.
- Nanox.ARC (product) — The stationary X-ray system that received FDA clearance.
- U.S. Food and Drug Administration (FDA) (company) — The regulatory body that granted the clearance.
- December 5, 2024 (date) — The date the announcement was made and clearance was received.
FAQ
What specific indications has the Nanox.ARC received FDA 510(k) clearance for?
The Nanox.ARC has received clearance for general use in producing tomographic images for human musculoskeletal system, pulmonary, intra-abdominal, and paranasal sinus indications in adult patients.
When did Nano-X Imaging Ltd. announce this FDA clearance?
Nano-X Imaging Ltd. announced the FDA clearance on December 5, 2024.
What type of X-ray system is the Nanox.ARC?
The Nanox.ARC is a stationary X-ray system.
Is the Nanox.ARC intended for pediatric use?
The filing states the Nanox.ARC is intended for adult patients.
What is the significance of the 510(k) clearance from the FDA?
A 510(k) clearance indicates that the FDA has determined the device is substantially equivalent to a legally marketed predicate device, allowing it to be marketed in the U.S.
Filing Stats: 283 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-12-05 06:04:31
Filing Documents
- ea0223535-6k_nano.htm (6-K) — 13KB
- ea022353501ex99-1_nano.htm (EX-99.1) — 15KB
- 0001213900-24-105748.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NANO-X IMAGING LTD . By: /s/ Ran Daniel Name: Ran Daniel Title: Chief Financial Officer Date: December 5, 2024 3